慢性肾脏疾病(CKD)和糖尿病可能的药物治疗的当前主题

Y. Kato, H. Bando, Sayuri Matsuzaki, S. Waka
{"title":"慢性肾脏疾病(CKD)和糖尿病可能的药物治疗的当前主题","authors":"Y. Kato, H. Bando, Sayuri Matsuzaki, S. Waka","doi":"10.15406/PPIJ.2020.08.00284","DOIUrl":null,"url":null,"abstract":"The authors and colleagues have been involved in Non-Communicable Diseases (NCDs), especially including diabetes, chronic kidney disease (CKD) and hemodialysis. Some topics are described as possible therapy for CKD. (i) Metformin has inhibitory effect on cardiovascular events, and has an evidence for safe administration in mild to moderate renal impairment. (ii) Canagliflozin reduced moderately cardiovascular and renal outcomes across the primary and secondary prevention groups, from mega studies of CANVAS and CREDENCE. (iii) erythropoiesis stimulating agent (ESA) has been effective for improving anemia in HD for years. Some hypoxia-inducible factor (HIF) seems to be applied for clinical practice soon.","PeriodicalId":19839,"journal":{"name":"Pharmacy & Pharmacology International Journal","volume":"77 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2020-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":"{\"title\":\"Current topics of possible pharmacotherapy for chronic kidney disease (CKD) and diabetes\",\"authors\":\"Y. Kato, H. Bando, Sayuri Matsuzaki, S. Waka\",\"doi\":\"10.15406/PPIJ.2020.08.00284\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The authors and colleagues have been involved in Non-Communicable Diseases (NCDs), especially including diabetes, chronic kidney disease (CKD) and hemodialysis. Some topics are described as possible therapy for CKD. (i) Metformin has inhibitory effect on cardiovascular events, and has an evidence for safe administration in mild to moderate renal impairment. (ii) Canagliflozin reduced moderately cardiovascular and renal outcomes across the primary and secondary prevention groups, from mega studies of CANVAS and CREDENCE. (iii) erythropoiesis stimulating agent (ESA) has been effective for improving anemia in HD for years. Some hypoxia-inducible factor (HIF) seems to be applied for clinical practice soon.\",\"PeriodicalId\":19839,\"journal\":{\"name\":\"Pharmacy & Pharmacology International Journal\",\"volume\":\"77 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-04-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmacy & Pharmacology International Journal\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.15406/PPIJ.2020.08.00284\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacy & Pharmacology International Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15406/PPIJ.2020.08.00284","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 2

摘要

作者及其同事参与了非传染性疾病(NCDs)的研究,特别是糖尿病、慢性肾脏疾病(CKD)和血液透析。一些主题被描述为CKD的可能治疗方法。(i)二甲双胍对心血管事件有抑制作用,并且有证据表明,在轻中度肾功能损害中使用二甲双胍是安全的。(ii) canag列净在一级和二级预防组中中度降低心血管和肾脏结局,来自CANVAS和CREDENCE的大型研究。(iii)促红细胞生成剂(ESA)多年来一直是改善HD患者贫血的有效药物。一些缺氧诱导因子(HIF)有望应用于临床。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Current topics of possible pharmacotherapy for chronic kidney disease (CKD) and diabetes
The authors and colleagues have been involved in Non-Communicable Diseases (NCDs), especially including diabetes, chronic kidney disease (CKD) and hemodialysis. Some topics are described as possible therapy for CKD. (i) Metformin has inhibitory effect on cardiovascular events, and has an evidence for safe administration in mild to moderate renal impairment. (ii) Canagliflozin reduced moderately cardiovascular and renal outcomes across the primary and secondary prevention groups, from mega studies of CANVAS and CREDENCE. (iii) erythropoiesis stimulating agent (ESA) has been effective for improving anemia in HD for years. Some hypoxia-inducible factor (HIF) seems to be applied for clinical practice soon.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Pilot study to compare the use of the national program drugs ALONE versus their combination with Artemisia Afra infusions for the treatment of pulmonary tuberculosis Gender differences in MS related pain, correlation with MRI lesion localization and burden of disease The efficacy and safety of silodosin-a review of literature Tribenoside–lidocaine combination in wound healing of hemorrhoids: a review of literature The effectively of favipiravir as antiviral therapy in the treatment of covid-19 in the several hospital in Blora, Indonesia
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1